Market Trends of Global Endometriosis Treatment Industry
This section covers the major market trends shaping the Endometriosis Treatment Market according to our research experts:
Pain Medication segment is Expected to Witness Significant Growth Over the Forecast Period
Endometriosis is associated with painful symptoms such as chronic pelvic pain, dysmenorrhea and dyspareunia, infertility, and psychological suffering among others. The medical treatment of endometriosis can deal with painful symptoms of the disease and, consequently, reduce the negative impact on quality of life and mental health. The medication has a high safety profile, good tolerance, few side effects, and reasonable costs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common pain medications for endometriosis. Over-the-counter NSAIDs include aspirin, ibuprofen, and naproxen. NSAIDs block the development of prostaglandins, a type of biological compound produced in the body. Prostaglandins cause swelling, pain, and inflammation that many women with endometriosis experience during their periods.
Furthermore, a continuous collaboration by major players in the market is positively affecting the growth of the segment. For instance, in February 2022 ObsEva SA announced a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across global markets outside of the United States, Canada, and Asia. Linzagolix is in development as a potential treatment for endometriosis-associated pain, and ObsEva recently announced positive topline results for its first Phase 3 trial (EDELWEISS 3) in this indication.
North America is Expected to Dominate the Endometriosis Treatment Market
North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products, the rising prevalence of endometriosis, and awareness about health in this region. For instance, according to the data published by the Office on Women's Health in 2021, endometriosis affects more than 11% of women between ages 15 and 44 and is common among women in their 30s and 40s in the United States.
Key product launches, high concentration of market players, or manufacturer's presence in the United States are some of the factors driving the growth of the endometriosis Treatment Market in the country. For instance, in August 2022, Myovant Sciences and Pfizer announce United States Food and Drug Administration (FDA) approved MYFEMBREE for the management of moderate to severe pain associated with endometriosis in pre-menopausal women. The drug offers a once-daily effective treatment option for the management of moderate to severe endometriosis pain, with a treatment duration of up to 24 months. Therefore, owing to the above-mentioned factors North America Endometriosis Treatment Market is expected to dominate and register higher growth over the forecast period.
